The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Hologic Inc. (NSDQ:HOLX) won a $15 million contract from the U.S. Defense Dept. to supply radiology products to the military and federal agencies.
The Bedford, Mass.-based company will provide its radiology systems, subsystems and components to the U.S. Army, Navy, Air Force, Marine Corps and other, civilian agencies. The contract is set to close April 6, 2011.
Hologic Inc. (NSDQ:HOLX) is touting interim results from a clinical trial of its Cervista test for the human papilloma virus.
The study of the test, designed to detect 14 high-risk strains of the virus, compared it with the Hybrid Capture 2 test made by Dutch diagnostics giant Qiagen. It’s a major cervical cancer screening trial involving more than 10,000 Chinese women. The preliminary results from data from about half of those patients indicates that the two tests are "clinically equivalent," according to a press release.
Hologic Inc. (NSDQ:HOLX) agreed to pay $12.5 million to Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon Endo-Surgery to settle a pair of patent infringement cases involving breast biopsy technology.
Ethicon sued Hologic in 2007 in Ohio and in 2009 in Delaware, accusing the Bedford, Mass.-based women’s health products maker of violating a quartet of patents related to Ethicon’s Mammotome breast biopsy system with Hologic’s ATEC system, and of violating false advertising laws.
Hologic Inc. (NSDQ:HOLX) wants a federal judge in Ohio to reconsider his ruling allowing Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon Endo-Surgery Inc. to pursue patent infringement claims in its lawsuit over breast biopsy technology.
Ethicon sued Hologic in 2007, accusing the Bedford, Mass.-based women’s health products maker of violating a quartet of patents related to Ethicon’s Mammotome breast biopsy system with Hologic’s ATEC system, and of violating false advertising laws.
Hologic Inc. (NSDQ:HOLX) took another tangible hit to its bottom line, writing off about $100 million worth of intangibles during the first quarter.
In all, the Bedford, Mass.-based women’s health company peeled off a little more than $100 million worth of intangible assets, an accounting term for the value of the perceived advantage a company has over its competitors. The hit, combined with another $18 million charge to adopt new changes to its accounting code, pushed Hologic’s bottom line down 31 percent during the three months ended Dec. 26, 2009.
A federal judge in Ohio threw out one patent infringement charge made against Hologic Inc. (NSDQ:HOLX) by Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon Endo-Surgery Inc., but ruled that four other claims in the suit must be sorted out at trial.
Ethicon sued Hologic in 2007, accusing the Bedford, Mass.-based women’s health products maker of violating a quartet of patents related to Ethicon’s Mammotome breast biopsy system with Hologic’s ATEC system, and of violating false advertising laws. Hologic asked Judge Michael Barrett of the U.S. District Court for Southern Ohio to rule two of the Ethicon patents invalid.
Hologic Inc. (NSDQ:HOLX) inked a deal with the U.S. Environmental Protection Agency to settle alleged hazardous waste violations at a Third Wave Technologies facility in Madison, Wis.
The Bedford, Mass.-based women’s health products company, which bought Third Wave in 2008 for $580 million, agreed to pay an $87,400 penalty to settle the case.
Hologic Inc. posted a massive second-quarter loss after taking a $2.34 billion write-down of goodwill and intangible assets on its acquisitions of Cytyc and Third Wave Technologies.
THe Bedford-based women’s health products maker’s stock slipped more than 10 percent in after-hours trading today, to $14 per share, after posting a high of $15.72 during the day.
